{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:37:41Z","timestamp":1792197461529,"version":"4.4.0"},"reference-count":115,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Critical Care"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.jcrc.2010.08.005","type":"journal-article","created":{"date-parts":[[2010,10,18]],"date-time":"2010-10-18T05:56:18Z","timestamp":1287381378000},"page":"225.e1-225.e10","source":"Crossref","is-referenced-by-count":48,"title":["The value of amphotericin B in the treatment of invasive fungal infections"],"prefix":"10.1016","volume":"26","author":[{"given":"Michael","family":"Klepser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.jcrc.2010.08.005_bb0005","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/504490","article-title":"Invasive fungal pathogens: current epidemiological trends","volume":"43","author":"Pfaller","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0010","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/376906","article-title":"A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients","volume":"37","author":"Pappas","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0015","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study","volume":"39","author":"Wisplinghoff","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0020","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1128\/JCM.42.4.1519-1527.2004","article-title":"Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program","volume":"42","author":"Hajjeh","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0025","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/315193","article-title":"Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole","volume":"181","author":"Marr","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0030","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1128\/AAC.38.6.1422","article-title":"Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period","volume":"38","author":"Price","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0035","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1086\/342300","article-title":"Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999","volume":"35","author":"Trick","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0040","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1086\/319985","article-title":"Invasive mold infections in allogeneic bone marrow transplant recipients","volume":"32","author":"Baddley","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0045","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0163-4453(98)80173-4","article-title":"An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group","volume":"37","author":"Denning","year":"1998","journal-title":"J Infect"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0050","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/339202","article-title":"Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients","volume":"34","author":"Marr","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0055","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0732-8893(03)00013-0","article-title":"Aspergillosis caused by non-fumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus","volume":"46","author":"Torres","year":"2003","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0060","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1086\/383319","article-title":"Fusarium infection in hematopoietic stem cell transplant recipients","volume":"38","author":"Nucci","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0065","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/590004","article-title":"Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis","volume":"47","author":"Chamilos","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0070","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1086\/428780","article-title":"Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases","volume":"191","author":"Kontoyiannis","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0075","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1086\/378745","article-title":"Attributable mortality of nosocomial candidemia, revisited","volume":"37","author":"Gudlaugsson","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0080","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1086\/502581","article-title":"Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance","volume":"26","author":"Morgan","year":"2005","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0085","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1086\/496922","article-title":"The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis","volume":"41","author":"Zaoutis","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0090","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1086\/323900","article-title":"The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis","volume":"33","author":"Perfect","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0095","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00005792-200007000-00006","article-title":"Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group","volume":"79","author":"Patterson","year":"2000","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0100","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ijid.2008.02.013","article-title":"The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups","volume":"13","author":"Tong","year":"2009","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0105","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0110","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/jac\/44.2.151","article-title":"The 1998 Garrod lecture. Current and future antifungal therapy: new targets for antifungal agents","volume":"44","author":"Andriole","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0115","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1128\/JCM.41.8.3623-3626.2003","article-title":"Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi","volume":"41","author":"Diekema","year":"2003","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0120","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1086\/504492","article-title":"Pharmacology of systemic antifungal agents","volume":"43","author":"Dodds Ashley","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0125","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1128\/AAC.43.5.1264","article-title":"Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole","volume":"43","author":"Oakley","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0130","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1128\/AAC.46.4.1032-1037.2002","volume":"46","author":"Pfaller","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0135","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1056\/NEJMc061720","article-title":"Multiple-triazole-resistant aspergillosis","volume":"356","author":"Verweij","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0140","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/jac\/dkn022","article-title":"Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods","volume":"61","author":"Alastruey-Izquierdo","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0145","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1128\/AAC.46.1.62-68.2002","article-title":"In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates","volume":"46","author":"Meletiadis","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0150","series-title":"Dilflucan [package insert]","year":"2004"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0155","series-title":"Noxafil [package insert]","year":"2008"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0160","series-title":"Sporanox [package insert]","year":"2006"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0165","series-title":"Vfend [package insert]","year":"2006"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0170","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drug monitoring: established and emerging indications","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0175","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1592\/phco.27.12.1627","article-title":"Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease","volume":"27","author":"Krishna","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0180","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.46.8.2546-2553.2002","article-title":"Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens","volume":"46","author":"Purkins","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0185","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/j.1552-4604.1988.tb03159.x","article-title":"Fluconazole penetration into cerebrospinal fluid in humans","volume":"28","author":"Foulds","year":"1988","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0190","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1086\/377131","article-title":"Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients","volume":"37","author":"Lutsar","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0195","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1128\/AAC.45.6.1854-1859.2001","article-title":"Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model","volume":"45","author":"Gonzalez","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0200","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1128\/AAC.47.4.1376-1381.2003","article-title":"In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms","volume":"47","author":"Nakai","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0205","series-title":"Cancidas [package insert]","year":"2005"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0210","series-title":"Eraxis [package insert]","year":"2006"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0215","series-title":"Mycamine [package insert]","year":"2005"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0220","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.2165\/00003495-200464180-00001","article-title":"Newer systemic antifungal agents: pharmacokinetics, safety and efficacy","volume":"64","author":"Boucher","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0225","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","article-title":"Echinocandin antifungal drugs","volume":"362","author":"Denning","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0230","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1086\/431761","article-title":"Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis","volume":"41","author":"Gauthier","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0235","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s10156-008-0612-5","article-title":"Ocular distribution of intravenously administered micafungin in rabbits","volume":"14","author":"Suzuki","year":"2008","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0240","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/QCO.0b013e328307c79c","article-title":"Echinocandins: a wealth of choice\u2013how clinically different are they?","volume":"21","author":"Zaas","year":"2008","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0245","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1128\/AAC.40.2.279","article-title":"Antifungal agents: chemotherapeutic targets and immunologic strategies","volume":"40","author":"Georgopapadakou","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0250","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1128\/AAC.42.3.528","article-title":"Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis","volume":"42","author":"Diamond","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0255","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1128\/JCM.30.11.2881-2886.1992","article-title":"Susceptibility testing of Cryptococcus neoformans: a microdilution technique","volume":"30","author":"Ghannoum","year":"1992","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0260","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1007059005753","article-title":"Microbiological characteristics and susceptibility patterns of strains of Rhodotorula isolated from clinical samples","volume":"145","author":"Galan-Sanchez","year":"1999","journal-title":"Mycopathologia"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0265","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1128\/JCM.43.9.4902-4904.2005","article-title":"Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis","volume":"43","author":"Pavie","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0270","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1128\/JCM.41.11.5233-5235.2003","article-title":"Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates","volume":"41","author":"Zaas","year":"2003","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0275","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1128\/AAC.38.11.2541","article-title":"Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichosporonosis","volume":"38","author":"Anaissie","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0280","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1128\/JCM.28.7.1616-1622.1990","article-title":"Trichosporon beigelii, an emerging pathogen resistant to amphotericin B","volume":"28","author":"Walsh","year":"1990","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0285","series-title":"Amphocin [package insert]","year":"2003"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0290","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1592\/phco.25.5.690.63591","article-title":"Experience with community-based amphotericin B infusion therapy","volume":"25","author":"Malani","year":"2005","journal-title":"Pharmacotherapy"},{"issue":"Suppl 1","key":"10.1016\/j.jcrc.2010.08.005_bb0295","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/jac\/49.suppl_1.37","article-title":"Amphotericin B nephrotoxicity","volume":"49","author":"Deray","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0300","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1086\/514672","article-title":"Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia","volume":"27","author":"White","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0305","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1128\/AAC.50.2.674-684.2006","article-title":"Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models","volume":"50","author":"Andes","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0310","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1128\/AAC.01449-06","article-title":"Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis","volume":"51","author":"Lewis","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0315","article-title":"Comparative pharmacodynamics of amphotericin B lipid complex (ABLC) and liposomal amphotericin B (L-AMB) in a murine model of acute invasive pulmonary zygomycosis","author":"Lewis","year":"2008"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0320","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1128\/AAC.00315-06","article-title":"Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model","volume":"50","author":"Olson","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0325","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1086\/315643","article-title":"Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system","volume":"182","author":"Groll","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0330","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1128\/AAC.48.3.1047-1050.2004","article-title":"Comparative efficacies of four amphotericin B formulations\u2013Fungizone, amphotec (Amphocil), AmBisome, and Abelcet\u2013against systemic murine aspergillosis","volume":"48","author":"Clemons","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0335","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1128\/AAC.42.4.899","article-title":"Comparison of fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis","volume":"42","author":"Clemons","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0340","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1128\/AAC.01488-07","article-title":"Comparison of lipid amphotericin B preparations in treating murine zygomycosis","volume":"52","author":"Ibrahim","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0345","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1128\/AAC.49.12.4867-4875.2005","article-title":"Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis","volume":"49","author":"Clemons","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0350","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S1473-3099(02)00371-7","article-title":"Antifungal drug resistance to azoles and polyenes","volume":"2","author":"Masia Canuto","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0355","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1099\/mic.0.2007\/010405-0","article-title":"Candida albicans drug resistance another way to cope with stress","volume":"153","author":"Cannon","year":"2007","journal-title":"Microbiology"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0360","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/01.tp.0000173771.47698.7b","article-title":"Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole","volume":"80","author":"Alexander","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0365","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1128\/AAC.49.2.767-769.2005","article-title":"Multiechinocandin-and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis","volume":"49","author":"Moudgal","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0370","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1128\/AAC.47.10.3149-3154.2003","article-title":"Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States","volume":"47","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0375","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1128\/JCM.42.10.4419-4431.2004","article-title":"Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus","volume":"42","author":"Pfaller","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0380","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1473-3099(02)00181-0","article-title":"Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences","volume":"2","author":"Sanglard","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0385","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1128\/AAC.42.10.2645","article-title":"Mechanism of fluconazole resistance in Candida krusei","volume":"42","author":"Orozco","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0390","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1128\/AAC.00148-06","article-title":"Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy","volume":"50","author":"Hakki","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0395","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1128\/AAC.48.4.1382-1383.2004","article-title":"Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis","volume":"48","author":"Hernandez","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0400","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1128\/AAC.00067-07","article-title":"Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase","volume":"51","author":"Kahn","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0405","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1086\/500939","article-title":"Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient","volume":"42","author":"Krogh-Madsen","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0410","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/jac\/dkl022","article-title":"Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis","volume":"57","author":"Laverdiere","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0415","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1128\/AAC.49.8.3264-3273.2005","article-title":"Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates","volume":"49","author":"Park","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0420","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1128\/AAC.43.5.1289","article-title":"Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from a multicenter prospective study of candidemia","volume":"43","author":"Clancy","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0425","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1128\/AAC.18.1.158","article-title":"Incidence of polyene-resistant yeasts recovered from clinical specimens","volume":"18","author":"Dick","year":"1980","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0430","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3201\/eid1203.050670","article-title":"Aspergillus ustus infections among transplant recipients","volume":"12","author":"Panackal","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0435","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1139\/m77-058","article-title":"Sterol content and polyene antibiotic resistance in isolates of Candida krusei, Candida parakrusei, and Candida tropicalis","volume":"23","author":"Safe","year":"1977","journal-title":"Can J Microbiol"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0440","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/596757","article-title":"Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0445","doi-asserted-by":"crossref","first-page":"5395","DOI":"10.1128\/JCM.43.10.5395-5396.2005","article-title":"Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation","volume":"43","author":"Girmenia","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0450","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0455","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0460","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00431-004-1606-7","article-title":"Failure of voriconazole to cure disseminated zygomycosis in an immunocompromised child","volume":"164","author":"Ritz","year":"2005","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0465","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1086\/422723","article-title":"Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis","volume":"39","author":"Siwek","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0470","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.bmt.1705614","article-title":"Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy","volume":"39","author":"Trifilio","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0475","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1086\/339215","article-title":"2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer","volume":"34","author":"Hughes","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0480","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0485","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/427759","article-title":"Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia","volume":"40","author":"Oren","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0490","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1086\/427752","article-title":"Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required","volume":"40","author":"Vigouroux","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0495","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/QCO.0b013e328307c7d9","article-title":"Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: clinical implications of recent studies","volume":"21","author":"Marr","year":"2008","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0500","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1600-0609.2006.00805.x","article-title":"Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies","volume":"78","author":"Maertens","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0505","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1086\/504810","article-title":"Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study","volume":"43","author":"Garey","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0510","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1128\/AAC.49.9.3640-3645.2005","article-title":"Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality","volume":"49","author":"Morrell","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0515","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/jac\/dkm212","article-title":"Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections","volume":"60","author":"Parkins","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0520","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"340","author":"Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0525","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/510677","article-title":"Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts","volume":"44","author":"Segal","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0530","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1086\/322631","article-title":"Improving efficacy of antifungal therapy by polymerase chain reaction-based strategy among febrile patients with neutropenia and cancer","volume":"33","author":"Lin","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0535","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1086\/496927","article-title":"Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study","volume":"41","author":"Maertens","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0540","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/597395","article-title":"Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial","volume":"48","author":"Cordonnier","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0545","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1086\/313750","article-title":"Practice guidelines for the management of patients with blastomycosis. Infectious Diseases Society of America","volume":"30","author":"Chapman","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.jcrc.2010.08.005_bb0550","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1470-9465.2004.00839.x","article-title":"Infections due to emerging and uncommon medically important fungal pathogens","volume":"10","author":"Walsh","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0555","first-page":"1165","article-title":"Update on the treatment of disseminated fusariosis: Focus on voriconazole","volume":"3","author":"Stanzani","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0560","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.50.1.126-133.2006","article-title":"Posaconazole as salvage therapy for zygomycosis","volume":"50","author":"Greenberg","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0565","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiload Trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0570","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1136\/bmj.322.7286.579","article-title":"Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomized controlled trial","volume":"322","author":"Eriksson","year":"2001","journal-title":"Br Med J"},{"key":"10.1016\/j.jcrc.2010.08.005_bb0575","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/jac\/dkh403","article-title":"Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients","volume":"54","author":"Peleg","year":"2004","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883944110002212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883944110002212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T00:59:20Z","timestamp":1592009960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0883944110002212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":115,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S0883944110002212"],"URL":"https:\/\/doi.org\/10.1016\/j.jcrc.2010.08.005","relation":{},"ISSN":["0883-9441"],"issn-type":[{"value":"0883-9441","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}